logo

For the Inventor, By the Inventor

Osaka, Japan

Masahiro Mizuno

This inventor holds 4 USPTO granted patents and 2 EPO patents. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2005-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masahiro Mizuno. Retrieved from https://idiyas.com/inventor/masahiro-mizuno-hlx8bqpy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 4

% Patents Active = 75.0


Average Co-Inventor Count = 6.3

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Mishima-gun, JP (2005)
  • Osaka, JP (2013 - 2023)

Company Filing History:

goldMedal4 out of 1,232 
 
Takeda Pharmaceutical Company Limited
 patents

Years Active: 2005-2023

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents
1. 11746109 - Crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate (2023-09-05),
2. 11524957 - Process for the synthesis of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one (2022-12-13),
3. 8373007 - Stable vinamidinium salt and nitrogen-containing heterocyclic ring synthesis using the same (2013-02-12),
4. 6949648 - Condensed pyrazole derivatives, process for producing the same and use thereof (2005-09-27),

Title: Masahiro Mizuno: Innovator in Pharmaceutical Chemistry

Introduction

Masahiro Mizuno is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target cell division and cancer treatment. With a total of four patents to his name, Mizuno's work is recognized for its potential impact on medical science.

Latest Patents

Mizuno's latest patents include innovative formulations and processes related to a compound known as 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate. This patent details the crystalline forms of the compound, methods for preparing these forms, and their applications in pharmaceutical compositions. Additionally, he has developed processes for synthesizing this compound, which serves as a Cdc7 kinase inhibitor, useful in treating disorders related to cell proliferation, particularly cancer.

Career Highlights

Mizuno is currently associated with Takeda Pharmaceutical Company Limited, where he continues to advance his research and development efforts. His work has been instrumental in creating new therapeutic options for patients suffering from various forms of cancer. His innovative approach to pharmaceutical chemistry has garnered attention in the scientific community.

Collaborations

Mizuno has collaborated with notable colleagues, including Kazuhiro Maeda and Tsuneo Yasuma. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the quality and impact of their research.

Conclusion

Masahiro Mizuno's contributions to pharmaceutical chemistry exemplify the importance of innovation in the fight against cancer. His patents and ongoing research continue to pave the way for new treatments that could significantly improve patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…